Lunit and SITC Join Forces to Advance AI in Immuno-Oncology

Lunit, a leading AI company specializing in medical imaging and diagnostics, has partnered with the Society for Immunotherapy of Cancer (SITC) to launch an exclusive research program. This collaboration aims to provide SITC members with temporary free access to Lunit SCOPE IO, an AI-driven biomarker discovery platform. The program, named the Lunit Research Program, is designed to expand AI biomarker research in immuno-oncology and foster collaboration between academia and industry.



Lunit SCOPE IO is an AI-powered tool trained on large-scale hematoxylin and eosin (H&E) slide image data. It quantifies tumor-infiltrating lymphocytes (TILs), a key indicator of immunotherapy response, and analyzes the tumor microenvironment (TME) to classify immune phenotypes into three categories: inflamed, immune-excluded, and immune-desert. By offering this tool to SITC members, Lunit and SITC aim to accelerate innovation and discovery in immuno-oncology research.

The Lunit Research Program is open to SITC members affiliated with academic or nonprofit research institutions who hold an MD or PhD. Applicants must have expertise in oncology, pathology, or immunology and will be selected based on their research proposal and CV. The application period runs through April 30, with selections taking two to three months. Research is expected to begin in the summer.

This partnership between Lunit and SITC is a significant step towards the broader adoption and integration of AI in immuno-oncology research and clinical practice. By providing access to AI-powered tools, validating AI technology in clinical settings, demonstrating AI's potential in combination therapies, and expanding AI capabilities, the collaboration is driving innovation and accelerating the development of personalized and targeted treatments for cancer patients.

In conclusion, the Lunit and SITC partnership is poised to revolutionize immuno-oncology research and diagnostics by harnessing the power of AI. Through the Lunit Research Program, researchers will gain access to cutting-edge AI technology, enabling them to explore the potential of AI in cancer diagnostics and therapeutics. This collaboration is a testament to the growing importance of AI in healthcare and its potential to transform cancer care.